23 Jul, 2026
Infertility is a global problem due to increased psychological and mental diseases caused by a sedentary lifestyle. A type of assisted reproductive technology called in-vitro fertilization is used to treat infertility. Preimplantation genetic testing identifies healthy embryos and reveals genetic abnormalities in the parents. The method helps choose a healthy IVF embryo by screening for genetic issues before implantation. Diagnostic and screening procedures are part of preimplantation genetic testing. Preimplantation genetic screening (PGS) transfers euploid embryos with a higher chance of implantation and live delivery. It helps identify disease-causing embryos and transfer unaffected embryos. PGD is conducted on couples who risk passing on a genetic problem to their offspring. In-vitro fertilization centers use the procedure to choose euploid embryos to transfer and improve clinical pregnancy, embryo implantation, and live birth rates.
According to epidemiological studies, children born to older mothers are more likely to be preterm and to experience a higher rate of chromosomal defects and congenital prenatal abnormalities. According to the American Academy of Family Physicians (AAFP), the likelihood of fetal chromosomal abnormalities increases progressively up to 30 and then rapidly after 30 years. Mexico is the only OECD country where the average age of women at childbirth is less than 28 years, whereas, in eight other nations, including Chile, Hungary, Latvia, Lithuania, Poland, the Slovak Republic, Turkey, and the United States, the average age is between 28 and 30 years.
IVF is widely used in developed and developing nations due to a decline in birth rates. Awareness of genomic risk has also grown as literacy has increased. Globally, genetic literacy has enhanced public attitude, comprehension, and interest. Rising public participation in personal genomics activities, including research and genomic services, has raised genetics awareness. Government-run training programs and direct-to-consumer (DTC) testing have led to a boom in genomic healthcare information.
The total cost of sequencing a human genome is estimated by the National Human Genome Research Institute (NHGRI) to drop from USD 4,000 in 2015 to USD 600 in 2022. Additionally, due to the continual and rapid rate of invention, the cost of sequencing the human genome will continue to decrease. More advanced reproductive infrastructure and technology have created opportunities for providing reproductive care across international borders. Preimplantation genetic testing demand will inevitably rise due to the current trend of reproductive tourism.
North America dominates the global preimplantation genetic testing market and is projected to reach USD 865.87 million by 2030, expanding at a CAGR of 8.40% during the forecast period. The U.S. and Canada contribute enormously to their market share in North America. The widespread acceptance of genetic testing and profiling in North America can be linked to the market's expansion. The U.S. is the most dominant country in revenue, contributing more than 91% of the North American market's revenue. Multinational firms invest a large amount of money in genetic testing companies to fund ongoing research projects to develop revolutionary sequencing technologies to improve testing capabilities.
sales@straitsresearch.com